Tumor lysis syndrome after treatment with gemcitabine for metastatic transitional cell carcinoma.
Tumor lysis syndrome is a set of life threatening complication that can arise from treatment of high tumor burden, drug sensitive, and rapidly proliferating neoplasm particularly of hematological origin. It is rarely described in patients with solid tumors. We report the first case of tumor lysis syndrome in a man with metastatic renal pelvic transitional cell carcinoma after gemcitabine treatment. Despite aggressive therapy, he died 2 weeks after TLS was diagnosed. Our experience demonstrates that administration of gemcitabine for metastatic renal pelvic transitional cell carcinoma may induce acute tumor lysis syndrome, which necessitates frequent laboratory monitoring and prompt initiation of appropriate therapeutic measures.
Lin
Cheng-Jui
CJ
Division of Nephrology, Department of Internal Medicine, Mackay Memorial Hospital, 92 Chung San North Road Section 2, Taipei, Taiwan. lincj@ms1.mmh.org.tw
Lim
Ken-Hong
KH
Cheng
Yi-Chou
YC
Chen
Han-Hsiang
HH
Wu
Chih-Jen
CJ
D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects* / Q000627:therapeutic use; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy*; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D015275:Tumor Lysis Syndrome / Q000175:diagnosis* / Q000209:etiology*; D000093542:Gemcitabine
D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000093542:Gemcitabine